104 studies found for:    ibrutinib
Show Display Options
Rank Status Study
1 Not yet recruiting Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
Condition: B-Cell Chronic Lymphocytic Leukemia
Interventions: Drug: Ibrutinib;   Drug: Erythromycin;   Drug: Voriconazole
2 Not yet recruiting Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Nivolumab;   Drug: Ibrutinib
3 Recruiting Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
Conditions: Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL);   Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
Intervention: Drug: Ibrutinib
4 Not yet recruiting A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Mesna;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: G-CSF;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Citrovorum
5 Completed A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants
Condition: Healthy Participants
Intervention: Drug: Ibrutinib
6 Recruiting A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants
Condition: Healthy
Interventions: Drug: Ibrutinib;   Drug: Moxifloxacin;   Drug: Ibrutinib-matching placebo;   Drug: Moxifloxacin-matching placebo
7 Recruiting Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Conditions: Adult B Acute Lymphoblastic Leukemia;   Chronic Lymphocytic Leukemia;   Cutaneous B-Cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   HIV Infection;   Intraocular Lymphoma;   Multicentric Angiofollicular Lymphoid Hyperplasia;   Nodal Marginal Zone Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Plasma Cell Myeloma;   Small Intestinal Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
8 Recruiting A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults
Condition: Healthy
Interventions: Drug: Ibrutinib (Treatment A) [Reference];   Drug: Ibrutinib (Treatment B);   Drug: Ibrutinib (Treatment C);   Drug: Ibrutinib (Treatment D);   Drug: Ibrutinib (Treatment E);   Drug: Ibrutinib (Treatment F)
9 Recruiting Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Drug: Ibrutinib;   Drug: Ifosfamide;   Other: Pharmacological Study;   Biological: Rituximab
10 Recruiting A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Behavioral: Phone Calls
11 Completed A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants
Condition: Healthy
Interventions: Drug: Ibrutinib;   Drug: Ketoconazole
12 Recruiting A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
Condition: Lung Cancer
Intervention: Drug: Ibrutinib
13 Recruiting Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)
Condition: Leukemia
Interventions: Drug: Ibrutinib;   Drug: Rituximab
14 Active, not recruiting Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Condition: Lymphoma, Mantle-cell
Intervention: Drug: Ibrutinib
15 Recruiting A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Conditions: Breast Cancer;   Non-Small Cell Lung Cancer;   Pancreatic Cancer
Interventions: Drug: Ibrutinib;   Drug: MEDI4736
16 Recruiting Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory CLL
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: Lenalidomide, Ibrutinib, Rituximab
17 Recruiting A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia (AML)
Interventions: Drug: Ibrutinib;   Drug: LD-AraC
18 Active, not recruiting PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Conditions: Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory/Relapsed Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Other: Correlative laboratory samples;   Other: quality of life assessment
19 Recruiting Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Pharmacological Study
20 Recruiting Ibrutinib and Palbociclib Isethionate in Treating Patients With Previously Treated Mantle Cell Lymphoma
Condition: Recurrent Mantle Cell Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Palbociclib;   Other: Pharmacological Study

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years